MedTrace Logo

Prediction of NEC With Urinary iFABP

NCT01805206 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-05-14

No results posted yet for this study

Summary

During the first four days of life, intestinal fatty acid binding protein (iFABP) is elevated in the urine of premature babies who go on to develop necrotizing enterocolitis (NEC) days to weeks later. This study aims to determine whether the withholding of feedings in babies with an elevated urinary iFABP can reduce the incidence of NEC.

Conditions

  • Prematurity
  • Necrotizing Enterocolitis

Interventions

OTHER

Assessment of urinary iFABP

OTHER

Administration of enteral feedings

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Gerald Gollin, MD · Loma Linda University School of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
2 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01805206 on ClinicalTrials.gov